Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include FirstWord Pharma, Endpoints News, Business Wire and BioPharma Dive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 22d ago.
Quick answers
Why is "Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdo" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Takeda's oral TYK2 zasocitinib tops Sotyktu in Phase III showdown FirstWord Pharma · 45d ago
- Takeda’s plaque psoriasis pill beats Bristol Myers’ Sotyktu in Phase 3 Endpoints News · 45d ago
- Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations Business Wire · 45d ago
- Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test BioPharma Dive · 45d ago
- Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown Fierce Biotech · 45d ago
Topics
Related trends
Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India
India has approved Takeda's Qdenga, marking the first time a dengue vaccine has been cleared for use within the country.
Bristol Myers says it will build pharma's 'most powerful' AI supercomputer with Nvidia
Bristol Myers Squibb is partnering with Nvidia to construct what it claims will be the most powerful AI supercomputer in the pharmaceutical industry.
Bob Myers goes on Rich Paul’s show, talks LeBron (duh), Jaylen Brown
NBA discourse intensifies as analysts and league insiders weigh in on potential free-agency moves for LeBron James, specifically regarding the Philadelphia 76ers.